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[PtCl2(NH3)(py)] by valproato ligands (VPA−1H) to yield trans-[Pt(VPA−1H)2(py)2] and trans-[Pt(VPA−1H)2
(NH3)(py)] respectively, significantly enhanced cytotoxicity against A2780 (parental) and A2780 cisR
(cisplatin resistant) ovarian cancer cells. The mutagenicity of trans-[Pt(VPA−1H)2(NH3)(py)] and trans-[Pt
(VPA−1H)2(py)2] was determined using the Ames test and is also reported.+353 1 402 2168.
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Currently nearly 50% of all anti-cancer therapies are platinum (Pt)-
based [1,2]. Surprisingly only three Pt-based drugs have been
approved for worldwide clinical use, namely cisplatin, carboplatin
and oxaliplatin (Fig. 1) while three others; nedaplatin, heptaplatin
and lobaplatin, have been approved only in Japan, South Korea and
China, respectively[1,3]. The cytotoxicity of Pt drugs is attributed to
their ability to bind DNA and thereby induce DNA damage and
ultimately apoptosis [3,4]. The application and efficacy of Pt drugs is
limited by drawbacks though such as (i) intrinsic or acquired
resistance and (ii) toxicity [3,4]. Therefore, strong incentives exist
for the development of innovative strategies that generate novel Pt
compounds which have different modes of action to those of clinically
used Pt drugs. It is conceivable that such novel Pt compounds would
potentially target a broader spectrum of human cancers, and in
particular cancers where resistance has already emerged to Pt drugs.
Farrell and co-workers initiated a resurgence of interest in the
development of trans Pt compounds as potential anti-cancer agents
[5,6]. Although transplatin for example (Fig. 2) is chemotherapeuti-
cally inactive, they demonstrated that substitution of the NH3 carrierligands of transplatin by N-donor heterocycles such as pyridine (py)
or thiazole activated a trans geometry. These so called “trans-platinum
planar amine” (TPA) complexes (Fig. 2) have comparable cytotoxi-
cities to those seen with both their cis-isomers and that of cisplatin,
while retaining activity against tumour cell lines resistant to cisplatin
[5–8]. Trans platinum compounds possessing alternative carrier
ligands to the N-donor heterocycles such as iminoethers, aliphatic
amines and aliphatic heterocyclic amines (Fig. 2) were also investi-
gated and shown to exhibit good activity [9,10].
More recently, Farrell and co-workers improved the profile of their
TPA complexes by replacing the chlorido leaving groups with
carboxylato ligands [11,12]. These trans-[Pt(O2CR)2(L)(L′)] (where L
and L′ are N-donor heterocycles or ammine ligands) or Pt compounds
with N2O2 donor sets have similar cytotoxicities to their N2Cl2
analogues but offer distinct advantages of being more water soluble,
stable to hydrolysis and displaying greater accumulation in cisplatin-
resistant tumour cells [11–14].
We are interested in combining platinum compounds with
molecularly targeted anti-cancer drugs, particularly histone deacety-
lase (HDAC) inhibitors (HDACIs) [15,16]. Histones are the main
protein component of chromatin, around which DNA coils. HDACs are
a class of zinc metalloenzymes that deacetylate core histone lysine
residues, which results in a condensed chromatin structure and
ultimately transcriptional repression [17]. Inhibition of HDAC function
therefore dramatically affects chromatin structure and thus function.
Cisplatin Carboplatin Oxaliplatin
Fig. 1. Structures of cisplatin, carboplatin and oxaliplatin.
Fig. 3. Structures of SAHA and VPA (HDAC inhibitors) and cis-[Pt(NH3)2(malSAHA−2H)].
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proteins such as proteins involved in cellular proliferation, migration,
death, DNA repair, angiogenesis, inflammation and the immune
response [18]. A range of structurally diverse HDACIs have been
shown to be effective anti-cancer agents via multiple mechanisms,
including inducing cell-cycle arrest, intrinsic and extrinsic apoptotic
mechanisms, mitotic cell death, autophagic cell death, generation of
reactive oxygen species, inhibiting angiogenesis, and improving NK
cell-mediated tumour immunity [17,18]. Several of these inhibitors
are now undergoing clinical trials [19]. Suberoylanilide hydroxamic
acid (SAHA, vorinostat), (Fig. 3) was the first FDA-approved pan-
HDACI to enter the clinic as a treatment for cutaneous T-cell
lymphoma [20]. SAHA is also well tolerated in patients, particularly
at doses which exhibit a potent anti-cancer effect [21,22].
We recently devised a strategy to derivatise SAHA in such away so as
to facilitate its binding to Pt,while not compromising itsHDAC inhibitory
activity. In doing so we developed a novel anti-cancer bifunctional
Pt drug candidate with dual DNA binding and HDAC inhibitory activity,
cis-[Pt(NH3)2(malSAHA−2H)] (Fig. 3) [15].
Valproic acid (VPA, 2-propylpentanoic acid), (Fig. 3), a clinically
used drug for the treatment of epilepsy, has also been shown to
possess HDAC inhibitory activity, along with anti-metastatic and anti-
cancer activities [23]. Consequently, it is currently undergoing clinical
trials as an anti-cancer agent either as a single agent, or as part of
different combination regimens [24]. In addition, VPA has been shown
to exhibit synergistic activity with cisplatin [25] and resensitise cells
that have acquired resistance to cisplatin [26].
Given our interest in Pt complexes [15,27–30] and HDAC inhibitors
[15,16,31], and the emergence of the TPA complexes with the N2O2
donor set [8], we sought to develop novel TPA complexes of VPA. We
speculated that VPA would enhance the activity of TPA complexes as
anti-cancer agents and in doing so target a broader spectrum of
human cancers than clinically used Pt drugs. We envisaged that our
TPA valproato complexes would hydrolyse in much the same way as
carboplatin [32,33] in cells but releasing valproato ligands free to
inhibit HDACs and the resulting cytotoxic TPA moiety free to bind
DNA nucleobases. Herein we describe the synthesis, characterisation,Fig. 2. Structures of transplatin and cytotoxic trans platinum compounin vitro cytotoxic activity against cisplatin sensitive and resistant
ovarian cancer cell lines (A2780 and A2780 cisR) and mutagenicity of
novel TPA valproato complexes.
2. Experimental
2.1. Materials and instrumentation
Sodium valproate, metal salts, solvents and deuterated solvents
were all purchased from Sigma Aldrich and used without further
purification. Trans-[PtCl2(NH3)(py)] and trans-[PtCl2(py)2] (where py is
pyridine) were prepared by the methods of Ma [11] and Kaufman [34],
respectively. IR spectrawere recorded asKBr discs (4000–400 cm−1) on
a Mattson Genesis II CSI FTIR spectrometer and the spectra analysed
using WinFirst software. 1H NMR spectra were recorded on a Bruker
Avance 400 NMR spectrometer and the spectra analysed using TopSpin
1 software. The residual undeuterated DMSO signal at 2.505 ppm was
used as an internal reference. Liquid chromatography–mass spectrom-
etry experiments were performed on a Quattro Micro quadrupole
electrospray mass spectrometer (Micromass, Waters Corp., USA): 10 μL
of the sampleswere injected in 300 μL of acetonitrile:water (60:40, v/v).
Themass spectrometrydatawere acquiredboth inpositiveandnegative
ionmodes. Elemental analysis (C, H, andN)were performed by the RCSI
Analytical Service, Department of Pharmaceutical and Medicinal
Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephens
Green, Dublin 2, Ireland.ds where py is pyridine, tz is thiazole and ipa is isopropylamine.
Table 1
Crystallographic data for trans-[Pt(VPA−1H)2(NH3)(py)].
Compound
Empirical formula C21 H38 N2 O4 Pt
Formula weight 577.62
Temperature 100(2) K
Wavelength 0.71073 Å
Crystal system Monoclinic
Space group P 2/c
a, Å 9.8826(11)
b, Å 10.8078(12)
c, Å 22.035(2)
β, ° 95.043(2)
Volume, Å3 2344.4(4)
Z 4
Density (calculated) 1.636 g/cm3
Absorption coefficient 6.012 mm−1
F(000) 1152
Crystal size, mm 0.12×0.10×0.01
Theta range for data collection 1.86 to 27.99
Reflections collected 42088
Independent reflections (R(int) 5617 (0.0820)
Completeness to theta=27.99 99.2%
Absorption correction Semi-empirical from equivalents
Max. and min. transmissions 0.942 and 0.463
Data/restraints/parameters 5617/0/261
Goodness-of-fit on F2 0.994
Final R indices [for 4062 rfln with I N2sigma(I)] R1=0.0342, wR2=0.0721
R indices (all data) R1=0.0597, wR2=0.0828
Largest diff. peak and hole, e.Å−3 1.859 and −1.426
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2.2.1. trans-[Pt(VPA−1H)2(NH3)(py)]
trans-[PtCl2(NH3)(py)] (0.18 g, 0.49 mmol) and AgNO3 (0.16 g,
0.95 mmol) in deionised water (6 mL) were stirred overnight in the
dark. The insoluble AgCl was filtered off and sodium valproate (0.18 g,
1.08 mmol) was added to the filtrate and the reaction stirred at room
temperature for 24 h. An off white solidwas filtered and dried over P2O5.
(0.125 g, 44%). (Found C, 43.7; H, 6.7; N, 4.7%. C21H38N2O4Pt requires C,
43.7; H, 6.3; N, 4.9%); 1H NMR δH (400 MHz, d6 DMSO, d=doublet,
t=triplet, s=singlet, br=broad, m=multiplet): 8.52 (d, 2H, 3J 5.2 Hz,
aromatic H), 8.03 (t, 1H, 3J 7.6 Hz, aromatic H), 7.54 (t, 2H, 3J 7.0 Hz,
aromatic H), 4.73 (s, 3H, br, NH3), 2.08 (m, 2H, CH), 1.33 (m, 4H, CH2),
1.11 (m, 12H, CH2), 0.79 (t, 12H, CH3); 13C NMR δC (100 MHz, d6 DMSO):
182.1 (C O), 151.60 (aromatic C), 138.62 (aromatic C), 125.33 (aromatic
C), 46.52 (CH valproato), 35.11 (CH2 valproato), 20.21 (CH2 valproato),
14.00 (CH3 valproato); IR νmax (cm−1, br=broad, s=strong, vs=very
strong) 3256 br, 3179 br, 2955 s, 2932 s, 2872 s, 1628 s, 1615 vs, 1609 vs,
1453 vs, 1383 vs. ESI-MS m/z: 578.19 (calcd. 578.24) ([M–H]+).
2.2.2. trans-[Pt(VPA−1H)2(py)2]
trans-[PtCl2(py)2] (0.25 g, 0.59 mmol) andAgNO3 (0.19 g, 1.17 mmol)
in a mixture of deionised water (6 mL) and DMF (4 mL) were stirred at
60 °C in the dark for 24 h. The insoluble AgCl was filtered off and sodium
valproate (0.22 g, 1.29 mmol) was added to the filtrate and the reaction
stirred at room temperature for 24 h. An off white solid was filtered and
dried over P2O5 (0.06 g, 16%). (Found C, 48.5; H, 6.2; N, 4.3%.
C26H40N2O4Pt requires C, 48.8; H, 6.3; N, 4.4%); 1H NMR δH (400 MHz,
d6 DMSO): 8.66 (dd, 4H, 3J 4.8 Hz, 4J 1.6 Hz, aromatic H), 8.00 (m, 2H,
aromaticH), 7.53 (m,4H, aromaticH), 2.03 (m,2H,CH),1.22 (m,4H,CH2),
1.05 (m, 4H, CH2), 0.78 (m, 8H, CH2), 0.64 (t, 12H, CH3); 13C NMR δC
(100 MHz, d6 DMSO): 183.90 (C O), 150.98 (aromatic C), 137.66
(aromatic C), 123.73 (aromatic C), 45.41 (CH valproato), 34.29 (CH2
valproato), 18.99 (CH2 valproato), 11.57 (CH3valproato); IRνmax (cm−1),
2954 s, 2931 s, 2871 s, 1629 vs, 1602 vs, 1452 vs, 1380 vs. ESI-MS m/z:
640.23 (calcd. 640.26) ([M–H]+).
2.3. Crystallographic measurements on trans-[Pt(VPA-1H)2(NH3)(py)]
Single crystals of trans-[Pt(VPA−1H)2(NH3)(py)] suitable for anX-ray
studywere obtained by slow evaporation from themother liquor and as
thin plates with relatively weak reflection ability. Crystal data (Table 1)
was collected on SMART APEX2 CCD diffractometer at 100 K using
monochromated Mo–Kα radiation, (λ=0.71073 Å). An analysis of the
measured intensities was carried out with the SAINT and SADABS
programmes included in the APEX2 programme package [35], taking
into account an absorption correction by the semi-empirical method.
The structureswere solved by the directmethods and refinedby the full-
matrix least-squares procedure against F2 in anisotropic approximation.
Ammonium hydrogen atoms were located in the difference Fourier
maps andwere then shifted at the standard X-ray values for N―Hbonds
(0.9 Å) and included in the refinement using riding approximation (Uiso
(H)=1.2Ueq(N)). All the other hydrogen atoms were placed in
geometrically calculated positions and refined within riding model
(Uiso(H)=nUeq(C), where n=1.5 for methyl hydrogen atoms and
n=1.2 for all the other hydrogens). The refinementwas carried outwith
the SHELXTL programme [36].
2.4. Mutagenicity
The possible genotoxicity of test agents was investigated using the
Standard Ames bacterial mutation assay described by Maron and Ames
[37]. The primary tester strains used were Salmonella typhimurium
strains TA98 and TA100 (Trinova, Germany), which detect mutation by
frame-shift and base-pair substitution, respectively. Both strains carry
the ampicillin resistance plasmid pKM101. Tester strains were culturedin Oxoid nutrient broth No. 2 to a cell density of 1×109 cells/mL (OD of
0.60 at 605 nm) and maintained on master plates for routine inocu-
lation. Both tester strains were then grown on minimal glucose plates,
supplemented with 0.5 mM histidine/biotin and ampicillin.
To carry out the Ames test, top agar [0.3% (w/v) agar and 0.5% (w/v)
NaCl] was supplemented with 10 mL of 0.5 mM histidine/biotin per
100 mL of agar, immediately prior to use. A 2 mL aliquot of top agarwas
distributed into a sterile universal. A mammalian enzyme activation
system was also included, which consisted of the S9 liver fraction of a
male Sprague–Dawley rat, inducedwith aroclor 1254. A 500 μl aliquot of
S9 mixture (10%, v/v), 100 μl of test agent at the appropriate
concentration dissolved in 0.1 M PBS, pH 7.4, and 100 μl of tester strains
were added to 2 mL aliquots of molten top agar, mixed and quickly
poured over the surface of minimal glucose plates lacking histidine/
biotin. All plates were then protected from light, allowed to solidify,
inverted and then incubated at 37 °C for 72 h. Following incubation, the
number of revertant colonies was determined per plate. Each test
concentration was analysed in triplicate, in both the presence and
absence of the S9 enzyme activation system. Negative control plates
used consisted of tester strain and S9 mix alone, while the solvent-
treated control consisted of tester strain, S9mixture and solvent vehicle
(no test agent). This approach allowed identification and quantification
of spontaneous bacterial revertants. Positive controls included the
known mutagens, 4-nitroquinoline-N-oxide (NQNO) for TA98 (1–
1000 ng/plate) and sodium azide (0.5–10 μg/plate) for TA100. The
metabolising activity of the rat liver S9 was tested in both strains using
2-aminoanthracene, as this mutagen required metabolic activation in
order to induce mutations.
2.5. In vitro cytotoxicity
The in vitro anti-cancer chemotherapeutic potential of our test
agents was determined using two human-derived malignant ovarian
model cell lines; A2780 and A2780 cisR. Both cell lines were purchased
from the European Collection of Cell Cultures and maintained in RPMI-
1640mediawith Earle's balanced salt solution (EBSS) containing 1.5 g/L
sodium bicarbonate, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL
streptomycin, along with 10% (v/v) foetal bovine serum (FBS). All cell
Fig. 4. ORTEP view (drawn at 50% probability of thermal displacement ellipsoids) of trans-[Pt(VPA−1H)2(NH3)(py)] molecules A(left) and A′(right). Two symmetrically disordered
components of NH3 group shown by solid and open lines, correspondingly. Atoms labelled with letters A are generated by a two-fold symmetry axis.
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otherwise stated.
The cisplatin-resistant human ovarian cell line, namely A780 cisR,
was previously developed by chronic exposure of the parent cisplatin
sensitive A2780 cell line to increasing concentrations of cisplatin. A2780
cisR cells are known to be cross-resistant to melphalan, adriamycin and
irradiation.Resistancewasmaintainedby, every thirdpassage, culturing
these cells in 1 μM cisplatin, and cells were maintained as above. Both
model cell lines were incubated at 37 °C in a humidified atmosphere,
containing 95% air with 5% CO2.
Each of the two cell lines (100 μl) were seeded at a density of 5×104
cells/mL into sterile 96 wells of flat-bottomed plates and grown in 5%
CO2 at 37 °C. Test compounds were dissolved in dimethylformamide
(DMF) and diluted with complete culture media. The maximum
percentage of DMF present in all wells was 0.5% (v/v). Each drug
solution (100 μl)was added to replicatewells in the concentration range
of 1–100 μM,and incubated for 72 h.Aminiaturised viability assayusing
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
was carried out according to the method described previously [38].
The IC50 value for each drug was calculated and this is defined as the
drug concentration causing a 50% reduction in cellular viability. Each
assay was carried out using five replicates and repeated on three
separate occasions. Viability was calculated as a percentage of solvent-
treated control cells, and expressed as a % of control. The significance of
any reduction in cellular viability was determined using one-way
ANOVA (analysis of variance). A probability of 0.05 or less was deemed
statistically significant.Table 2
Selected bond lengths (Å) and angles (°) for trans-[Pt(VPA−1H)2(NH3)(py)].
Bond, Å Molecule A Molecule A′
Pt1–O1 2.008(4) 2.017(4)
Pt1–N1 1.998(6) 2.017(6)
Pt1–N2 2.026(6) 2.050(6)
Bond angle, ° Molecule A Molecule A′
O1–Pt1–N1 91.95(10) 90.91(10)
O1–Pt1–N2 88.05(10) 89.09(10)
O1–Pt1–O1A 176.1(2) 178.2(2)
N1–Pt1–N2 180.000(2) 180.000(2)
Atoms denoted with letter A are generated by a two-fold symmetry axis.3. Results and discussion
3.1. Syntheses of platinum valproic acid complexes
The TPA precursors, trans-[PtCl2(NH3)(py)] and trans-[PtCl2(py)2]
were reacted with silver nitrate to give the corresponding nitrato
compounds, which were subsequently reacted with sodium valproate
to give trans-[Pt(VPA−1H)2(NH3)(py)] and trans-[Pt(VPA-1H)2(py)2]
respectively.
Both complexes were formed in reasonably poor yields (44% and
16% for trans-[Pt(VPA−1H)2(py)2] and trans-[Pt(VPA−1H)2(NH3)(py)]
respectively) and characterised by elemental analysis, infrared and 1H
NMRspectroscopy andmass spectrometry. Elemental-analytical data for
both complexes are consistent with the presence of diam(m)ine Pt(II)
moieties bound to two VPA−1H ligands and the absence of counterions
suggesting neutral complexes. The presence of two VPA−1H ligands per
Pt(II) centre suggests also that the VPA−1H ligands are coordinated in a
monodentate fashion.
IR spectroscopy proved a particularly useful technique for character-
isation of themetal carboxylato complexes and assisted in confirming the
coordination modes of the VPA−1H ligand. Carboxylic acids may
coordinate metals in a monodentate, bidentate or bridging mode and
metal carboxylato complexes display asymmetric, νa(COO), and sym-
metric, νs(COO), stretching bands [39]. The IR spectra of trans-[Pt
(VPA−1H)2(NH3)(py)] and trans-[Pt(VPA−1H)2(py)2] display νa(COO)
bands at ca. 1630 cm−1 (KBr), showing a shift to lower wavenumbers
than in the uncoordinated VPA (1706 cm−1, liquid film) as well as
symmetric stretching νs(COO) bands at ca. 1380 cm−1 (KBr). In addition
theΔvalues [νa(COO)-νs(COO)] for thePt complexes (ca. 250) are greater
than the Δ values for the corresponding carboxylate ion (e.g. sodium
valproate, KBr, and 144). This observation supports the hypothesis thatTable 3
H-bonding parameters for trans-[Pt(VPA-1H)2(NH3)(py)]⁎.
D-H…A d(D-H), Å d(D…A), Å d(H…A), Å bDHA, °
N2-H2B…O2′A 0.90 2.812 2.051 142
N2-H2D…O2′ 0.90 2.812 2.141 131
N2′-H2B′…O2 0.90 2.895 2.104 146
N2′-H2D′…O2B 0.90 2.895 2.194 134
⁎ Atoms denotedwith letters A and B are generated by symmetry codes−x, y,−z+1/2
and−x+1, y,−z+1/2, correspondingly.
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In the 1H NMR spectrum of trans-[Pt(VPA−1H)2(py)2] the pyridine
proton signals (C9, C11 and C10, see Fig. 4, where NH3 is replaced with
pyridine for trans-[Pt(VPA−1H)2(py)2] and the two pyridines have
identical numbering), are found at 8.66, 8.00 and 7.53 ppm respectively
and integrate for 10 protons. The methine (C2), methylene (C3 and C4)
and methyl (C5) proton signals of the bound VPA−1H ligands are found
at 2.03, 1.22, 1.05 and 0.78 ppm and integrate in total for 30 protons.
In the 1H NMR spectrum of trans-[Pt(VPA−1H)2(NH3)(py)] the
pyridine proton signals (C9, C11 and C10, Fig. 4) are found at 8.52, 8.03
and 7.54 ppm respectively but integrate for 5 protons in total. In trans-
[Pt(VPA−1H)2(NH3)(py)] the ammine proton signal is found at
4.73 ppmand integrates for threeprotons. Themethine (C2),methylene
(C3 and C4) and methyl (C5) proton signals of the bound VPA−1H
ligands, Fig. 4, are found at 2.08, 1.33, 1.11 and 0.79 ppm and also
integrate in total for 30 protons.
In the 13C NMR spectrum of both symmetrical complexes the
carbonyl carbon signal (C1) is found at ca. 183 ppm and the three
pyridine carbon signals (C9, C11 and C10) are found at ca. 150, 138
and 125 ppm respectively, Fig. 4. The methine (C2), methylene (C3
and C4) and methyl (C5) carbon signals of the bound VPA−1H ligands,
Fig. 4, are found at ca. 46, 35, 20 and 13 ppm respectively for both
complexes.
ESI-MS in the positive mode was used to assist in identifying the
platinum complexes; mass peaks at 640.23 and 578.19 amu were
observed for trans-[Pt(VPA−1H)2(py)2] and trans-[Pt(VPA−1H)2(NH3)
(py)] respectively. All of the spectra display the correct isotopic patterns.
An X-ray crystal structure was solved for trans-[Pt(VPA−1H)2(NH3)
(py)].A
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Fig. 5. StandardAmes testswere used to determine themutagenic potential of all test compoun
fraction isolated fromrat hepatocytes. Results presented for (A) TA98 (−)S9 and (B) TA98 (+)S93.2. Crystal structure of trans-[Pt(VPA−1H)2(NH3)(py)]
The atomic numbering scheme and atom connectivity for trans-[Pt
(VPA−1H)2(NH3)(py)] is shown in Fig. 4 and a selection of bond
lengths and angles are reported in Table 2.
An asymmetric unit cell of trans-[Pt(VPA−1H)2(NH3)(py)] contains
two halves of Pt-complexes (A and A′) which are both located on the
two-fold symmetry axes. The ammine protons are disordered over two
symmetrical positions with equal occupancies. A general view of these
molecules is shown in Fig. 4. In both complexes, the platinum atom
adopts square planar geometry. All the N–Pt–N, N–Pt–O and O–Pt–O
angles are nearly 90° and 180°, correspondingly (see Table 1). The
valproic carboxylato groups in both molecules are nearly perpendicular
to the alkyl chains of the valproato ligands. The disparity between the
two independent Pt complexes is in the orientation of the pyridine
ligand. There is a difference in rotation about Pt1–N1(Pt1′–N1′) bond; in
molecule A the torsion angle for O1–Pt1–N1–C9 is−59.4(3)° where as
inmolecule A′ it is−23.0(3)°. This results in a slightly shortened C9′-H9′
A…O1′ contact (C…O is 2.960(7)Å, H…O is 2.42 Å, bCHO is 116°) in A′.
Inmolecule A, this distance corresponds to a normal nonbonded contact
(H9…O1 is3.02 Å, noH-bond is formed). Therefore theorientationof the
pyridine ring is predominantly defined by the effect of the crystal
packing rather than by the intramolecular C–H…O interaction.
In the crystal, the Pt molecules are connected to each other by a
H-bond network. The ammine protons are H-bonded to the carboxylato
O2(O2′) atoms (Table 3). This leads to the formation ofH-bond chains in
the direction of the a axis. Each chain is built up of alternate A and A′
molecules. In the ab plane, these chains are interpenetrated by pyridine
moieties. Two adjacent pyridine rings from different chains are nearly
perpendicular to each other; the closest intermolecular distance ispy)2]
trans
-[PtCl2
(NH3)(
py)]
trans
-[Pt(VP
A)2(NH
3)(py)]
DMF (0.5% v/v)
10 ng
100 ng
1000 ng
10000 ng
py)2]
trans
-[PtCl2
(NH3)(
py)]
trans
-[Pt(VP
A)2(NH
3)(py)]
DMF (0.5% v/v)
10 ng
100 ng
1000 ng
10000 ng
ds using TA 98 Salmonella typimurium tester strain, both in the presence and absence of a S9
, for test agents at a concentration range of 10–10,000 ng/plate. Bars indicate±SEM,n=3.
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not imply any strong interchain interactions but such packing is
responsible for the different orientation of the pyridine rings in A andA′.
3.3. Mutagenicity
Themutagenicity of our test agents was determined using the Ames
test and the data is presented in Figs. 5 and 6. For a compound to be
considered as a possible mutagen, a fold-related increase in revertant
colonies must be observed with increasing concentration. Data
presented shows that trans-[Pt(VPA−1H)2(NH3)(py)] increased the
number of revertant colonies in both TA98 and 100 cells both with
and without S9. By contrast, trans-[PtCl2(NH3)(py)] was only found to
be mutagenic in TA100 cells, and in the presence of the S9 fraction.
Therefore, trans-[Pt(VPA−1H)2(NH3)(py)] and trans-[PtCl2(NH3)(py)]
may be considered possible mutagens, a trend similar to that observed
for cisplatin [40,41].
3.4. In vitro cytotoxicity
The in vitro anti-cancer chemotherapeutic potential of a series of
TPA dichlorido compounds and their corresponding TPA valproato
analogues were determined using two human-derived ovarian cancer
cell lines; parental cell line A2780 and cisplatin resistant variant
A2780 cisR. Dose–response curves were plotted (data not shown) and
used to calculate IC50 values (Table 4). Sodium valproate and
transplatin were shown to be inactive in both cell lines. Additionally,
the TPA compounds; trans-[PtCl2(py)2] and trans-[PtCl2(NH3)(py)]
exhibited little or no cytotoxicity at the maximum concentration used
(100 μM). Previously it has been shown that when the NH3 group ofA
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Fig. 6. Standard Ames tests were used to determine the mutagenic potential of all test compo
of a S9 fraction isolated from rat hepatocytes. Results presented for (A) TA100 (−)S9 and
indicate±SEM, n=3.transplatin is substituted with N-donor heterocycle ligands, such as
pyridine, a cytotoxicity profile equivalent to that of cisplatin was
observed [6]. In our study, we demonstrated that replacement of the
dichlorido ligands in trans-[PtCl2(py)2] and trans-[PtCl2(NH3)(py)] by
valproato ligands (VPA−1H) to yield trans-[Pt(VPA−1H)2(py)2] and
trans-[Pt(VPA−1H)2(NH3)(py)] respectively, significantly enhanced
cytotoxicity against A2780 and A2780 cisR cells. We also established
that cytotoxicity was marginally enhanced in the cisplatin-resistant
phenotype (A2780 cisR) over the parental phenotype (A2780) when
cells were treated with both valproic acid complexes, trans-[Pt
(VPA−1H)2(py)2] and trans-[Pt(VPA−1H)2(NH3)(py)]. Interestingly,
Lin et. al. described how valproic acid was capable of re-sensitising
cisplatin-resistant ovarian cancer cells in vitro [24] and Farrell and co-
workers demonstrated that TPA compounds of the N2O2 donor set
displayed greater accumulation in cisplatin-resistant tumour cells
[13]. Cisplatin (e.g. IC50 value of 2.9 μM against A2780) and Farrell and
co-worker's TPA carboxylato complexes, in contrast, are significantly
more cytotoxic (e.g. IC50 values of b20 μM against A2780) than trans-
[Pt(VPA−1H)2(py)2] and trans-[Pt(VPA−1H)2(NH3)(py)][13]. Farrell's
complex, trans-[Pt(O2CH)2(NH3)(4-pic)], (4-pic = 4 picolinic acid),
which displayed the fastest hydrolysis andwas themost water soluble
of the TPA complexes studied had an IC50 of 6 μM against the A2780
cell line for example [13].4. Conclusion
The first examples of Pt complexes of the well known anti-epilepsy
drug and HDAC inhibitor, valproic acid, trans-[Pt(VPA−1H)2(py)2] and
trans-[Pt(VPA−1H)2(NH3)(py)] are reported. Valproic acid type ligands
can bind to Pt(II) centres via the carboxylato functionality and in apy)2]
trans
-[PtCl2
(NH3)(
py)]
trans
-[Pt(VP
A)2(NH
3)(py)]
DMF (0.5% v/v)
10 ng
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1000 ng
10000 ng
py)2]
trans
-[PtCl2
(NH3)(
py)]
trans
-[Pt(VP
A)2(NH
3)(py)]
DMF (0.5% v/v)
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1000 ng
10000 ng
unds using TA100 Salmonella typimurium tester strain, both in the presence and absence
(B) TA100 (+)S9, for test agents at a concentration range of 10–10,000 ng/plate. Bars
Table 4
IC50 values (μM) (mean±S.E.M.; n=3) for test agents was determined using A2780
and A2780 cisR following 72 h of incubation. A graph of viability vs drug concentration
was used to calculate all resultant IC50 values.
Cytotoxicity mean IC50 (μM)±S.E.M.
Test agent A2780 A2780cisR
Cisplatin 2.9±0.1 28.5±1.5
Transplatin N100 N100
Sodium Valproate N100 N100
trans-[PtCl2(py)2] N100 N100
trans-[Pt(VPA−1H)2(py)2]. N100 95.1±7.30
trans-[PtCl2(NH3)(py)] N100 N100
trans-[Pt(VPA−1H)2(NH3)(py)] 86.5±1.20 76.3±4.20
799D.M. Griffith et al. / Journal of Inorganic Biochemistry 105 (2011) 793–799monodentate manner. The X-ray crystal structure of the novel complex
trans-[Pt(VPA−1H)2(NH3)(py)] is also described. Replacement of the
dichlorido ligands in TPA complexes significantly enhanced cytotoxicity
against A2780 (parental) and A2780 cisR (cisplatin resistant) ovarian
cancer cells. It is envisaged that development of TPA carboxylato
complexes, where the carboxylic acid ligand is a more potent HDACI
than valproic acid and one which would contribute positively to the
hydrolysis and solubility profile of corresponding Pt complexes, may
serve to enhance the cytotoxic potential of TPA complexes.
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ANOVA analysis of variance
DMF dimethylformamide
EBSS Earle's balanced salt solution
FBS foetal bovine serum
HAT histone acetyltransferase
HDAC histone deacetylase
HDACI histone deacetylase inhibitor
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide
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ipa isopropylamine
ORTEP Oak Ridge Thermal Ellipsoid Plot
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4-pic 4 picolinic acid
py pyridine
SAHA suberoylanilide hydroxamic acid
TPA trans-platinum planar amine
tz thiazole
VPA valproic acid, 2-propylpentanoic acid
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free of charge from The Director, CCDC, 12 Union Road, Cambridge CB2
1EZ, UK (fax:++44-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk or
www: http://www.ccdc.cam.ac.uk/products/csd/request/). Supple-
mentary data to this article can be found online at doi: 10.1016/j.
jinorgbio.2011.03.001.References
[1] M. Galanski, M.A. Jakupec, B.K. Keppler, Curr. Med. Chem. 12 (2005) 2075–2094.
[2] N.J. Wheate, S. Walker, G.E. Craig, R. Oun, Dalton Trans. 39 (2010) 8113–8127.
[3] L. Kelland, Nat. Rev. 7 (2007) 573–584.
[4] Y. Jung, S.J. Lippard, Chem. Rev. 107 (2007) 1387–1407.
[5] N. Farrell, T.T.B. Ha, J.P. Souchard, F.L. Wimmer, S. Cros, N.P. Johnson, J. Med. Chem.
32 (1989) 2240–2241.
[6] N. Farrell, L.R. Kelland, J.D. Roberts, M. Van Beusichem, Cancer Res. 52 (1992)
5065–5072.
[7] N. Farrell, L.F. Povirk, Y. Dange, G. DeMasters, M.S. Gupta, G. Kohlhagen, Q.A. Khan,
Y. Pommier, D.A. Gewirtz, Biochem. Pharmacol. 68 (2004) 857–866.
[8] S.M. Aris, N.P. Farrell, Eur. J. Inorg. Chem. (2009) 1293–1302.
[9] M. Coluccia, G. Natile, Anticancer Agents Med. Chem. 7 (2007) 111–123.
[10] U. Kalinowska-Lis, J. Ochocki, K. Matlawska-Wasowska, Coord. Chem. Rev.
252 (2008) 1328–1345.
[11] E.S.F. Ma, W.D. Bates, A. Edmunds, L.R. Kelland, T. Fojo, N. Farrell, J. Med. Chem.
48 (2005) 5651–5654.
[12] A.G. Quiroga, J.M. Perez, C. Alonso, C. Navarro-Ranninger, N. Farrell, J. Med. Chem.
49 (2005) 224–231.
[13] G.H. Bulluss, K.M. Knott, E.S.F. Ma, S.M. Aris, E. Alvarado, N. Farrell, Inorg. Chem.
45 (2006) 5733–5735.
[14] S.M. Aris, D.A. Gewirtz, J.J. Ryan, K.M. Knott, N.P. Farrell, Biochem. Pharmacol.
73 (2007) 1749–1757.
[15] D. Griffith, M.P. Morgan, C.J. Marmion, Chem. Commun. (2009) 6735–6737.
[16] D. Griffith, J.P. Parker, C.J. Marmion, Anticancer Agents Med. Chem. 10 (2010)
354–370.
[17] O.A. Botrugno, F. Santoro, S. Minucci, Cancer Lett. 280 (2009) 134–144.
[18] J.E. Shabason, P.J. Tofilon, K. Camphausen, Oncology 24 (2010) 180–185.
[19] S. Cang, Y. Ma, D. Liu, J. Hematol. Oncol. 2 (2009) 22.
[20] P.A. Marks, Oncogene 26 (2007) 1351–1356.
[21] W.K. Kelly, P.A. Marks, Nat. Clin. Pract. Oncologist 2 (2005) 150–157.
[22] M. Duvic, J. Vu, Expert Opin. Investig. Drugs 16 (2007) 1111–1120.
[23] A. Papi, A.M. Ferreri, P. Rocchi, F. Guerra, M. Orlandi, Anticancer Res. 30 (2010)
535–540.
[24] J. Hrebackova, J. Hrabeta, T. Eckschlager, Curr. Drug Targ. 11 (2010) 361–379.
[25] R.B. Erlich, D. Rickwood, W.B. Coman, N.A. Saunders, A. Guminski, Cancer
Chemother. Pharmacol. 63 (2009) 381–389.
[26] C.-T. Lin, H.-C. Lai, H.-Y. Lee, W.-H. Lin, C.-C. Chang, T.-Y. Chu, Y.-W. Lin, K.-D. Lee,
M.-H. Yu, Cancer Sci. 99 (2008) 1218–1226.
[27] D. Griffith, K. Lyssenko, P. Jensen, P.E. Kruger, C.J. Marmion, Dalton Trans. (2005)
956–961.
[28] D.M. Griffith, A. Haughey, S. Chahal, H. Müller-Bunz, C.J. Marmion, Inorg. Chim.
Acta 363 (2010) 2333–2337.
[29] D. Griffith, A. Bergamo, S. Pin, M. Vadori, H. Mueller-Bunz, G. Sava, C.J. Marmion,
Polyhedron 26 (2007) 4697–4706.
[30] D. Griffith, A. Chopra, H. Mueller-Bunz, C.J. Marmion, Dalton Trans. (2008)
6933–6939.
[31] D. Griffith, M. Devocelle, C.J. Marmion, in: A. Hughes (Ed.), Amino Acids, Peptides
and Proteins in Organic Chemistry, Wiley-VCH, Weinheim, 2009.
[32] R.W. Hay, S. Miller, Polyhedron 17 (1998) 2337–2343.
[33] M. Pavelka, M.F. Lucas, N. Russo, Chem. Eur. J. 13 (2007) 10108–10116.
[34] G.B. Kaufman, D.O. Cowan, Inorg. Synth. 7 (1963) 239–245.
[35] Bruker AXS Inc., APEX2 and SAINT, Madison, Wisconsin, USA, 2005.
[36] G.M. Sheldrick, Acta Cryst. A64 (2008) 112–122.
[37] D.A. Maron, B.N. Ames, Mutat. Res. 113 (1983) 173–215.
[38] T. Mosmann, J. Immunol. Meth. 65 (1983) 55–63.
[39] K. Nakamoto, Infrared and Raman Spectra of Inorganic and Coordination
Compounds Part B, John Wiley and Sons, New Jersey, 2009.
[40] H.J. Cross, M. Tilby, J.K. Chipman, D.R. Ferry, A. Gesher, Int. J. Cancer 3 (1996)
404–408.
[41] M.A. Hannan, A.A. Al-Dakan, S.S. Hussain, M.H. Amer, Toxicology 55 (1989)
183–191.
